Every 10-Q that Travere Therapeutics, Inc. (TVTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics reported total revenue of $169.584 million for the quarter ended June 30, 2026, up from $114.449 million a year earlier. Net product sales were $161.352 million, led by FILSPARI at $141.078 million versus $71.887 million in 2025, while tiopronin products declined modestly. License and collaboration revenue fell to $8.232 million from $19.607 million. Operating income was $3.954 million, but a $40.008 million inducement expense on repurchasing 2029 convertible notes drove a net loss of $34.797 million, or $0.37 per share.
For the first six months of 2026, revenue was $296.782 million and net loss was $71.899 million. Net cash provided by operating activities improved to $17.705 million from an outflow of $37.211 million in 2025. At June 30, 2026, cash and cash equivalents were $117.735 million and available-for-sale marketable debt securities were $371.442 million. Convertible senior notes totaled $602.781 million (net), including $525.0 million of new 0.50% notes due 2032 and $94.875 million of 2.25% notes due 2029, while stockholders’ equity was $24.522 million.
Business updates include full FDA approval on April 13, 2026 of FILSPARI to reduce proteinuria in adults and pediatric patients with FSGS, where FILSPARI is the first and only FDA‑approved medicine. The pegtibatinase Phase 3 HARMONY Study resumed enrollment in early 2026 with the first new patient dosed in April. Key risks highlighted include heavy dependence on FILSPARI commercialization, clinical and regulatory uncertainty for pipeline programs, reimbursement and pricing pressures, manufacturing reliance on third parties, substantial funding needs, and ongoing regulatory and litigation exposure.
Travere Therapeutics reported higher revenue but continued losses for the quarter ended March 31, 2026. Total revenue reached $127.2 million, up from $81.7 million a year earlier, driven mainly by FILSPARI sales.
Net product sales were $124.5 million, including $105.2 million from FILSPARI and $19.3 million from tiopronin products. The company recorded a net loss of $37.1 million, versus $41.2 million in the prior-year quarter, or $(0.40) per share.
Operating expenses rose to $164.1 million, reflecting higher research and development and selling, general and administrative costs, as well as royalty expense. Travere ended the quarter with $78.4 million in cash and cash equivalents and $186.3 million in marketable debt securities, against $312.1 million of convertible debt.
In April 2026, after quarter-end, the FDA granted full approval of FILSPARI for FSGS, making it the first approved medicine for this disease. Travere also restarted enrollment in its Phase 3 HARMONY study of pegtibatinase for classical homocystinuria and dosed the first new patient following the restart.
Travere Therapeutics (TVTX) reported a strong Q3 2025 turnaround. Total revenue was $164.9 million, up from $62.9 million a year ago, driven by net product sales of $113.2 million and license and collaboration revenue of $51.7 million.
FILSPARI sales reached $90.9 million, while tiopronin products contributed $22.3 million. Collaboration revenue included a $40.0 million market access milestone from CSL Vifor and $9.3 million recognized from the Renalys agreement; royalties from CSL Vifor territories added $2.4 million. Operating income was $24.9 million versus a loss last year, yielding net income of $25.7 million (diluted EPS $0.28).
Cash and cash equivalents were $110.9 million and marketable debt securities were $143.6 million, reflecting repayment of the 2025 notes. Shares outstanding were 89,456,626 as of September 30, 2025. The FDA is reviewing an sNDA for FILSPARI in FSGS with a PDUFA target action date of January 13, 2026; the FDA indicated an advisory committee meeting is no longer needed. Pegtibatinase’s Phase 3 HARMONY enrollment remains paused to finalize manufacturing scale-up, with patients continuing on study medication.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.